In light of this, we present four patients who received neoadjuvant targeted therapies for potentially resectable stage III NSCLC with oncogenic driver mutations (EGFR or ALK), with the goal of determining their efficacy in this setting. This evidence concerns the gene EGFR and non-small cell lung carcinoma.